Related to HemCon and Prometic to Develop Capture Device for Antibody Removal

• Sartorius Stedim and GE Healthcare Cross-License Biomanufacturing IP
  
• Ark to Manufacture PsiOxus’ IV-Administered Oncolytic Virus for Clinical Trials
  
• ImmunoCellular Therapeutics Chooses PCT for Supply of Glioblastoma Vaccine Candidate
  
• NIPTE Receives $35M from FDA to Reform Drug Manufacturing Standards
  
• GeoVax and Vivalis Sign Deal for the Biomanufacture of MVA HIV Vaccine in EB66 Cells
  
• Lonza to Manufacture Genmab’s Tissue Factor-Targeting Antibody-Drug Conjugate
  
• Repligen Buys Novozymes Biopharma Sweden for $22.7M
  
• GSK Taps Alnylam’s RNAi Technology for Vaccine Production
  
• Oxyrane Raises $26.5M to Take Lead Enzyme Replacement Therapy Through Phase I/II
  
• Aveo Signs BI on as Production Partner for Clinical-Stage mAb
  
• GE Healthcare, M+W to Bolster Biomanufacturing in Emerging Nations
  
• Renova to Develop Transgenic Rabbits for Pharming’s Recombinant FVIII Program
  
• Nanohale Acquires Scil Technology’s Development, Formulation, and Analytics Assets
  
• Sigma-Aldrich Snaps Up BioReliance for $350M
  
• ABL and MicroTest Separately Announce Contract Manufacturing Deals
  
• IntelliCell Licenses SVF Manufacturing Technology to Cell-Innovations
  
• PCT Inks Manufacturing and Service Deal with Islet for Diabetes Transplantation Therapy
  
• Sartorius Stedim, G-Con Partner to Offer Self-Contained Biomanufacturing Facilities
  
• Arabio Appoints Alphamed as Vaccines Distributor in UAE
  
• SGI and IDT Pool Expertise to Offer Small Synthetic Gene Products